BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35249442)

  • 1. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
    Collins J; Stump SE; Heiling H; Muir M; Deal A; Proco D; Nguyen C; Cozad M; Mato A; Coombs CC; Muluneh B
    Leuk Lymphoma; 2022 Aug; 63(8):1823-1830. PubMed ID: 35249442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.
    Williams AM; Baran AM; Casulo C; Reagan P; Friedberg JW; Helber M; Moore J; Baloga E; Zent CS; Barr PM
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):41-47. PubMed ID: 30409718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Barr PM; Brown JR; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Mulligan SP; Jaeger U; Furman RR; Cymbalista F; Montillo M; Dearden C; Robak T; Moreno C; Pagel JM; Burger JA; Suzuki S; Sukbuntherng J; Cole G; James DF; Byrd JC
    Blood; 2017 May; 129(19):2612-2615. PubMed ID: 28373262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.
    Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Jacobs R
    Patient Prefer Adherence; 2023; 17():2073-2084. PubMed ID: 37641660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
    Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
    Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution.
    Sekiguchi Y; Iizuka H; Takizawa H; Mitsumori T; Tomita S; Izumi H; Okubo M; Miyake K; Osawa T; Sawada T; Yoshikawa S; Noguchi M
    Gan To Kagaku Ryoho; 2021 Jul; 48(7):921-926. PubMed ID: 34267029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
    Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
    Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
    Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
    Ito Y; Makita S; Maeshima AM; Hatta S; Suzuki T; Yuda S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Intern Med; 2018 Aug; 57(16):2395-2398. PubMed ID: 29526963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Shibayama H; Teshima T; Choi I; Hatake K; Sekiguchi N; Yoshinari N
    J Clin Exp Hematop; 2019; 59(4):179-186. PubMed ID: 31866619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
    Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ibrutinib in relapsed/refractory CLL and SLL in Japan: a post-marketing surveillance.
    Omi A; Nomura F; Tsujioka S; Fujino A; Akizuki R
    J Clin Exp Hematop; 2022 Sep; 62(3):136-146. PubMed ID: 35831100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
    Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
    Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    Byrd JC; Brown JR; O'Brien S; Barrientos JC; Kay NE; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Devereux S; Barr PM; Furman RR; Kipps TJ; Cymbalista F; Pocock C; Thornton P; Caligaris-Cappio F; Robak T; Delgado J; Schuster SJ; Montillo M; Schuh A; de Vos S; Gill D; Bloor A; Dearden C; Moreno C; Jones JJ; Chu AD; Fardis M; McGreivy J; Clow F; James DF; Hillmen P;
    N Engl J Med; 2014 Jul; 371(3):213-23. PubMed ID: 24881631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
    Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
    Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
    Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data.
    Tombak A; Pepedil Tanrıkulu F; Durusoy SS; Dinçyürek HD; Kaya E; Ümit EG; Yavaşoğlu İ; Mehtap Ö; Deveci B; Özcan MA; Terzi H; Okay M; Sayınalp N; Yılmaz M; Okan V; Kızıklı A; Özcan Ö; Çetin G; Demircioğlu S; Aydoğdu İ; Saydam G; Davulcu EA; İlhan G; Uçar MA; Özet G; Akpınar S; Turgut B; Berber İ; Kurtoğlu E; Sönmez M; Batur DS; Yıldırım R; Özkocamaz V; Güneş AK; Sahip B; Ertop Ş; Akay OM; Baştürk A; Doğu MH; Akdeniz A; Ünal A; Seyhanlı A; Gürkan E; Çekdemir D; Ferhanoğlu B
    Turk J Haematol; 2021 Dec; 38(4):273-285. PubMed ID: 34448556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.